Combination Trastuzumab With Expanded Natural Killer Cells for Treating HER2-positive Gastric Cancer
Status:
Unknown status
Trial end date:
2020-01-01
Target enrollment:
Participant gender:
Summary
This trial is to evaluate the safety and effectiveness of activated and expanded in vitro
autologous NK cells following trastuzumab treatment for patients Human Epidermal Receptor-2
overexpressing advanced gastric cancer.